Problem

Most health data is episodic and fragmented: a conventional blood test offers a narrow snapshot, while people trying to improve energy, weight, inflammation, aging, or metabolic health need to understand what is happening across their bodies and whether interventions are working. iollo’s core insight is that the direction and rate of biomarker change can be more useful than a single measurement. Its main use case is an individual repeatedly testing while changing diet, exercise, supplements, or sleep, then using the results to make more informed wellness decisions. The economics are premium and consumer-paid, with plans priced from $299 to $459 per test, justified by the breadth of data, at-home convenience, and personalized interpretation rather than by diagnosis or treatment.

Product / Service

iollo sells an at-home blood-testing service that measures more than 500—and, on its current site, 600-plus—metabolites from one sample using mass spectrometry. Customers collect blood at home with a collection device, return it using a prepaid label, and receive results and recommendations after laboratory analysis, with the reported turnaround being three to five weeks. AI converts the biochemical data into reports covering areas such as biological age, metabolic, heart, liver, immune, digestive, inflammatory, hormonal, kidney, and gut health, while the service can also incorporate other laboratory results and wearable data.

The offering is designed as an ongoing health-optimization loop rather than a one-time result: users can track biomarker trends, see how their bodies respond to lifestyle changes, access raw data, and receive personalized diet, lifestyle, supplement, and AI-coaching guidance. The company explicitly positions the tests for wellness purposes only, not for medical advice or diagnosis.

Market

iollo competes at the intersection of consumer digital health, at-home diagnostics, metabolomics, longevity, and personalized wellness. Its positioning is differentiated by the depth of its metabolomics panel and by translating that data into consumer-facing recommendations. Tracxn identifies Oura, Masimo, and Endotronix in its competitor set, although these names suggest an adjacent health-monitoring and diagnostics landscape rather than identical products.

The company appears commercially active but still early-stage rather than clearly pre-revenue: its website offers paid plans and pre-orders, and PitchBook records completed accelerator and seed events with the company marked as generating revenue and having raised $500,000. GetLatka estimates approximately $440,000 of 2025 revenue, but public databases are inconsistent—PitchBook leaves current revenue blank and GetLatka also contains a conflicting zero-funding statement—so the revenue figure should be treated as directional rather than audited. The available evidence establishes early commercial traction, but not scale or a disclosed customer count.